Health behaviours and beliefs in individuals with familial pancreatic cancer.


Journal

Familial cancer
ISSN: 1573-7292
Titre abrégé: Fam Cancer
Pays: Netherlands
ID NLM: 100898211

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 16 9 2019
medline: 18 2 2020
entrez: 16 9 2019
Statut: ppublish

Résumé

Individuals at high risk for pancreatic cancer are recommended surveillance and healthy lifestyle behaviours and patient experience with recommendations are understudied. To describe engagement and experience with surveillance, tobacco and alcohol use, health beliefs and motivation (Champion Health Belief Measure) and the relationship with personal, psychosocial (Impact of Event Scale), and familial characteristics. Interest in integrative therapies (complementary therapies) are described. A multi-site cross-sectional survey including individuals at high risk for pancreatic cancer with no diagnosis of pancreatic cancer who have been evaluated at a comprehensive cancer center. Descriptive statistics and Wilcoxon rank sum test and Fisher's exact test were used to assess univariate associations. Of the 132 respondents (72% response rate), 92 (70%) reported undergoing surveillance which was associated with older age (p = 0.001). Of which, 36% and 51% report that magnetic resonance imaging (MRI) or endoscopic ultrasound (EUS), respectively, were uncomfortable; 22% and 30% dread the next MRI or EUS, respectively. Of those who reported alcohol consumption (n = 88); 15% consumed 1 or more drinks daily and no alcohol consumption was associated with higher Impact of Event scale scores (p = 0.024). A total of six participants were currently smoking every day or some days. Participants reported high motivation to engage in heathy behaviours and 92% were interested in integrative therapies. In these select participants, most were engaging in pancreatic cancer surveillance, alcohol intake was moderate, and tobacco intake was minimal. Modifiable factors, such as experience and comfort with surveillance could be addressed. The sample is motivated to engage in behavioural health intervention.

Identifiants

pubmed: 31522335
doi: 10.1007/s10689-019-00143-7
pii: 10.1007/s10689-019-00143-7
pmc: PMC6784816
doi:

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

457-464

Subventions

Organisme : NCATS NIH HHS
ID : KL2 TR001100
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA210170
Pays : United States

Références

JAMA. 2018 Jun 19;319(23):2383-2385
pubmed: 29922810
Fam Cancer. 2014 Mar;13(1):35-44
pubmed: 23934600
Gastroenterology. 2012 Apr;142(4):796-804; quiz e14-5
pubmed: 22245846
World J Gastroenterol. 2014 Aug 28;20(32):11182-98
pubmed: 25170203
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1893-8
pubmed: 17035396
Cancer Lett. 2016 Oct 10;381(1):269-77
pubmed: 27461582
Cancer Causes Control. 2010 Apr;21(4):513-21
pubmed: 20012181
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Soc Sci Med. 2008 Feb;66(3):790-800
pubmed: 18037204
Psychooncology. 2018 Jul;27(7):1711-1718
pubmed: 29570238
Psychooncology. 2016 Aug;25(8):971-8
pubmed: 26632416
Psychosom Med. 1979 May;41(3):209-18
pubmed: 472086
JAMA. 2018 Jun 19;319(23):2401-2409
pubmed: 29922827
Res Nurs Health. 1999 Aug;22(4):341-8
pubmed: 10435551
Genet Med. 2011 Dec;13(12):1015-24
pubmed: 21857231
CA Cancer J Clin. 2017 May 6;67(3):194-232
pubmed: 28436999
Hered Cancer Clin Pract. 2015 May 21;13(1):13
pubmed: 26029287
Am J Gastroenterol. 2015 Feb;110(2):223-62; quiz 263
pubmed: 25645574
CA Cancer J Clin. 2012 Jan-Feb;62(1):30-67
pubmed: 22237782
J Genet Couns. 2016 Oct;25(5):957-64
pubmed: 26659117

Auteurs

Meghan Underhill-Blazey (M)

Dana-Farber Cancer Institute, 450 Brookline Avenue, LW 522, Boston, MA, 02215, USA. meghanl_underhill@dfci.harvard.edu.

Traci Blonquist (T)

Dana-Farber Cancer Institute, 450 Brookline Avenue, LW 522, Boston, MA, 02215, USA.

Janette Lawrence (J)

Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.

Fangxin Hong (F)

Dana-Farber Cancer Institute, 450 Brookline Avenue, LW 522, Boston, MA, 02215, USA.

Matthew B Yurgelun (MB)

Dana-Farber Cancer Institute, 450 Brookline Avenue, LW 522, Boston, MA, 02215, USA.
Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02215, USA.

Sapna Syngal (S)

Dana-Farber Cancer Institute, 450 Brookline Avenue, LW 522, Boston, MA, 02215, USA.
Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02215, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH